1
|
Dieme A, Lemoine A, Linglart A, Tressol C, Javalet M, Tounian P, Benoist G. Corrigendum à « Apports calciques chez l’enfant suivi pour allergie aux protéines du lait de vache : évaluation et conseils pratiques en consultation » [Revue française d’allergologie 62/8 (2022) 709]. Revue Française d'Allergologie 2023. [DOI: 10.1016/j.reval.2023.103311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
2
|
Dieme A, Lemoine A, Linglart A, Tressol C, Javalet M, Tounian P, Benoist G. Apports calciques chez l’enfant suivi pour allergie aux protéines du lait de vache : évaluation et conseils pratiques en consultation. Revue Française d'Allergologie 2022. [DOI: 10.1016/j.reval.2022.07.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
3
|
Grandal B, Aljehani A, Dumas E, Daoud E, Jochum F, Gougis P, Hotton J, Lemoine A, Michel S, Laas E, Laé M, Pierga JY, Alaoui Ismaili K, Lerebours F, Reyal F, Hamy AS. No Impact of Seasonality of Diagnoses on Baseline Tumor Immune Infiltration, Response to Treatment, and Prognosis in BC Patients Treated with NAC. Cancers (Basel) 2022; 14:cancers14133080. [PMID: 35804852 PMCID: PMC9264787 DOI: 10.3390/cancers14133080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Revised: 06/15/2022] [Accepted: 06/20/2022] [Indexed: 12/10/2022] Open
Abstract
Simple Summary High tumor-infiltrating lymphocyte (TIL) levels are associated with an increased response to neoadjuvant chemotherapy (NAC) in breast cancer (BC). The seasonal fluctuation of TILs in breast cancer is poorly documented. In this study, we compared pre- and post-treatment immune infiltration, the treatment response as assessed by means of pathological complete response (pCR) rates, and survival according to the seasonality of BC diagnoses in a clinical cohort of patients treated with NAC. We found no association between seasonality and baseline TIL levels or pCR rates. We found that post-NAC stromal lymphocyte infiltration was lower when cancer was diagnosed in the summer, especially in the subgroup of patients with TNBC. Our data do not support the hypothesis that the seasonality of diagnoses has a major impact on the natural history of BC treated with NAC. Abstract Breast cancer (BC) is the most common cancer in women worldwide. Neoadjuvant chemotherapy (NAC) makes it possible to monitor in vivo response to treatment. Several studies have investigated the impact of the seasons on the incidence and detection of BC, on tumor composition, and on the prognosis of BC. However, no evidence is available on their association with immune infiltration and the response to treatment. The objective of this study was to analyze pre- and post-NAC immune infiltration as assessed by TIL levels, the response to treatment as assessed by pathological complete response (pCR) rates, and oncological outcomes as assessed by relapse-free survival (RFS) or overall survival (OS) according to the seasonality of BC diagnoses in a clinical cohort of patients treated with neoadjuvant chemotherapy. Out of 1199 patients, the repartition of the season at BC diagnosis showed that 27.2% were diagnosed in fall, 25.4% in winter, 24% in spring, and 23.4% in summer. Baseline patient and tumor characteristics, including notable pre-NAC TIL levels, were not significantly different in terms of the season of BC diagnosis. Similarly, the pCR rates were not different. No association for oncological outcome was identified. Our data do not support the idea that the seasonality of diagnoses has a major impact on the natural history of BC treated with NAC.
Collapse
Affiliation(s)
- Beatriz Grandal
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, 75005 Paris, France; (B.G.); (E.D.); (E.D.); (F.J.); (P.G.); (S.M.); (E.L.); (A.S.H.)
- Department of Surgical Oncology, Institut Curie, University Paris, 75005 Paris, France;
| | - Ashwaq Aljehani
- Department of Surgical Oncology, Institut Curie, University Paris, 75005 Paris, France;
- Department of Surgery, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11564, Saudi Arabia
| | - Elise Dumas
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, 75005 Paris, France; (B.G.); (E.D.); (E.D.); (F.J.); (P.G.); (S.M.); (E.L.); (A.S.H.)
| | - Eric Daoud
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, 75005 Paris, France; (B.G.); (E.D.); (E.D.); (F.J.); (P.G.); (S.M.); (E.L.); (A.S.H.)
| | - Floriane Jochum
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, 75005 Paris, France; (B.G.); (E.D.); (E.D.); (F.J.); (P.G.); (S.M.); (E.L.); (A.S.H.)
| | - Paul Gougis
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, 75005 Paris, France; (B.G.); (E.D.); (E.D.); (F.J.); (P.G.); (S.M.); (E.L.); (A.S.H.)
| | - Judicaël Hotton
- Department of Surgical Oncology, Institut Godinot, Université de Lorraine, 51100 Reims, France;
| | - Amélie Lemoine
- Department of Medical Oncology, Institut Godinot, Université de Lorraine, 51100 Reims, France;
| | - Sophie Michel
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, 75005 Paris, France; (B.G.); (E.D.); (E.D.); (F.J.); (P.G.); (S.M.); (E.L.); (A.S.H.)
- Department of Surgical Oncology, Institut Curie, University Paris, 75005 Paris, France;
| | - Enora Laas
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, 75005 Paris, France; (B.G.); (E.D.); (E.D.); (F.J.); (P.G.); (S.M.); (E.L.); (A.S.H.)
- Department of Surgical Oncology, Institut Curie, University Paris, 75005 Paris, France;
| | - Marick Laé
- Henri Becquerel Cancer Center, Department of Pathology, INSERM U1245, UniRouen Normandy University, 76130 Rouen, France;
- Department of Pathology, Institut Curie, University Paris, 75231 Paris, France
| | - Jean-Yves Pierga
- Department of Medical Oncology, Institut Curie, University Paris, 75231 Paris, France; (J.-Y.P.); (K.A.I.); (F.L.)
| | - Khaoula Alaoui Ismaili
- Department of Medical Oncology, Institut Curie, University Paris, 75231 Paris, France; (J.-Y.P.); (K.A.I.); (F.L.)
| | - Florence Lerebours
- Department of Medical Oncology, Institut Curie, University Paris, 75231 Paris, France; (J.-Y.P.); (K.A.I.); (F.L.)
| | - Fabien Reyal
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, 75005 Paris, France; (B.G.); (E.D.); (E.D.); (F.J.); (P.G.); (S.M.); (E.L.); (A.S.H.)
- Department of Surgical Oncology, Institut Curie, University Paris, 75005 Paris, France;
- Correspondence: ; Tel.: +33-144-324-660 or +33-615-271-980
| | - Anne Sophie Hamy
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, 75005 Paris, France; (B.G.); (E.D.); (E.D.); (F.J.); (P.G.); (S.M.); (E.L.); (A.S.H.)
- Department of Surgical Oncology, Institut Curie, University Paris, 75005 Paris, France;
- Department of Medical Oncology, Institut Curie, University Paris, 75231 Paris, France; (J.-Y.P.); (K.A.I.); (F.L.)
| |
Collapse
|
4
|
Lemoine A, Perrier M, Mazza C, Quinquenel A, Brasseur M, Delmer A, Vallerand H, Dewolf M, Bertin E, Barbe C, Botsen D, Bouché O. Feasibility and Impact of Adapted Physical Activity (APA) in Cancer Outpatients Beginning Medical Anti-Tumoral Treatment: The UMA-CHAPA Study. Cancers (Basel) 2022; 14:cancers14081993. [PMID: 35454896 PMCID: PMC9029046 DOI: 10.3390/cancers14081993] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Revised: 04/12/2022] [Accepted: 04/12/2022] [Indexed: 12/15/2022] Open
Abstract
Simple Summary Physical activity may reduce the risk of overall cancer incidence and improve survival in cancer patients. The beneficial effects of physical activity are also described in cancer survivors but remains poorly known during systemic cancer treatment. Therefore, we studied the feasibility of an adapted physical activity (APA) program in cancer outpatients beginning a medical anti-tumoral treatment for a digestive, lung, hematological, or dermatological cancer. We also studied the impact of APA on fatigue, anxiety, depression, and handgrip strength. Abstract Adapted physical activity (APA) improves quality of life and cancer outcomes. The aim of this study was to assess the feasibility of an APA program in outpatients beginning medical anticancer treatment. The secondary objective was to assess the impact of APA on fatigue, anxiety, depression, and handgrip strength (HGS). This prospective study was conducted between January and July 2017. Among 226 patients beginning treatment in the unit for a digestive, lung, hematological, or dermatological cancer, 163 were included. Adherence to the APA program was defined as more than or equal to one one-hour session per week for 3 months. The first evaluation was conducted at 3 months (M3), and the second evaluation at 6 months (M6). A total of 163 patients were included (mean age 62.5 ± 14.3); 139 (85.3%) agreed to follow the APA program. At M3, 106 of them were evaluated, of which 86 (81.1%) declared that they had followed the program. Improvement in anxiety was observed at M3 (−1.0 ± 3.2; p = 0.002) but there was no significant change in fatigue or depression. HGS decreased significantly (−1.2 ± 5.5; p = 0.04). The APA program was feasible in cancer outpatients beginning medical anticancer treatment. APA should be part of standard support care.
Collapse
Affiliation(s)
- Amélie Lemoine
- Department of Medical Oncology, Godinot Cancer Institute, 51100 Reims, France; (C.M.); (D.B.)
- Correspondence:
| | - Marine Perrier
- Department of Gastroenterology and Digestive Oncology, CHU Reims, University of Reims Champagne-Ardenne (URCA), 51100 Reims, France; (M.P.); (M.B.); (O.B.)
| | - Camille Mazza
- Department of Medical Oncology, Godinot Cancer Institute, 51100 Reims, France; (C.M.); (D.B.)
| | - Anne Quinquenel
- Department of Clinical Hematology, CHU Reims, 51100 Reims, France; (A.Q.); (A.D.)
| | - Mathilde Brasseur
- Department of Gastroenterology and Digestive Oncology, CHU Reims, University of Reims Champagne-Ardenne (URCA), 51100 Reims, France; (M.P.); (M.B.); (O.B.)
| | - Alain Delmer
- Department of Clinical Hematology, CHU Reims, 51100 Reims, France; (A.Q.); (A.D.)
| | - Hervé Vallerand
- Department of Pulmonary Medicine, CHU Reims, 51100 Reims, France; (H.V.); (M.D.)
| | - Maxime Dewolf
- Department of Pulmonary Medicine, CHU Reims, 51100 Reims, France; (H.V.); (M.D.)
| | - Eric Bertin
- Department of Nutrition, Endocrinology and Diabetology, CHU Reims, 51100 Reims, France;
| | - Coralie Barbe
- Research on Health University Department, University of Reims Champagne-Ardenne (URCA), 51100 Reims, France;
| | - Damien Botsen
- Department of Medical Oncology, Godinot Cancer Institute, 51100 Reims, France; (C.M.); (D.B.)
- Department of Gastroenterology and Digestive Oncology, CHU Reims, University of Reims Champagne-Ardenne (URCA), 51100 Reims, France; (M.P.); (M.B.); (O.B.)
| | - Olivier Bouché
- Department of Gastroenterology and Digestive Oncology, CHU Reims, University of Reims Champagne-Ardenne (URCA), 51100 Reims, France; (M.P.); (M.B.); (O.B.)
| |
Collapse
|
5
|
Lemoine A, Colas AS, Le S, Delacourt C, Tounian P, Lezmi G. Le syndrome d’entérocolite induite par les protéines alimentaires chez les enfants : une large cohorte multicentrique française. NUTR CLIN METAB 2022. [DOI: 10.1016/j.nupar.2021.12.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Mangiardi-Veltin M, Sebbag C, Rousset-Jablonski C, Ray-Coquard I, Berkach C, Laot L, Wang Y, Abdennebi I, Labrosse J, Sautter C, Toussaint A, Sablone L, Laas E, Khallouch S, Coussy F, Santulli P, Chapron C, Bobrie A, Jacot W, Sella N, Dumas E, Sénéchal-Davin C, Espie M, Giacchetti S, Maitrot L, Plu-Bureau G, Coutant C, Guerin J, Asselain B, Fumoleau P, Rodrigues M, Decanter C, Mailliez A, Delrieu L, Lemoine A, Jouannaud C, Houdre D, Reyal F, Hamy AS. Pregnancy, fertility concerns, and fertility preservation procedures in French breast cancer survivors in the FEERIC national study (on behalf of the Seintinelles research network). Reprod Biomed Online 2022; 44:1031-1044. [DOI: 10.1016/j.rbmo.2021.12.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Revised: 12/06/2021] [Accepted: 12/22/2021] [Indexed: 10/19/2022]
|
7
|
Andreazza P, Lemoine A, Coati A, Nelli D, Ferrando R, Garreau Y, Creuze J, Andreazza-Vignolle C. From metastability to equilibrium during the sequential growth of Co-Ag supported clusters: a real-time investigation. Nanoscale 2021; 13:6096-6104. [PMID: 33683240 DOI: 10.1039/d0nr08862e] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Atomic motions and morphological evolution of growing Co-Ag nanoparticles are followed in situ and in real time, by wide and small angle X-ray scattering obtained simultaneously in grazing incidence geometry (GISAXS and GIWAXS), in single or multi-wavelength anomalous modes. The structural analysis of the experimental data is performed with the aid of equilibrium Monte Carlo simulations and of molecular-dynamics simulations of nanoparticle growth. Growth is performed by depositing Co atoms above preformed Ag nanoparticles. This growth procedure is strongly out of equilibrium, because Ag tends to surface segregation, and generates complex growth sequences. The real time analysis of the growth allows to follow the nanoparticle evolution pathways almost atom-by-atom, determining the key mechanisms during Co deposition: starting with the incorporation of Co atoms in sub-surface positions, to the off-center Co domain formation, then by which the nanoparticles finally approach their equilibrium quasi-Janus then core-shell structures.
Collapse
Affiliation(s)
- P Andreazza
- Interfaces, Confinement, Matériaux et Nanostructures, ICMN, Université d'Orléans, CNRS, Orléans, France.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Blons H, Oudart JB, Merlio JP, Debieuvre D, de Fraipont F, Audigier-Valette C, Escande F, Hominal S, Bringuier PP, Fraboulet-Moreau S, Ouafik L, Moro-Sibilot D, Lemoine A, Langlais A, Missy P, Morin F, Souquet PJ, Barlesi F, Cadranel J, Beau-Faller M. PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project. Lung Cancer 2020; 151:69-75. [PMID: 33248711 DOI: 10.1016/j.lungcan.2020.11.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Revised: 10/22/2020] [Accepted: 11/10/2020] [Indexed: 01/09/2023]
Abstract
OBJECTIVES Tumor mutation screening is standard of care for patients with stage IV NSCLC. Since a couple of years, widespread NGS approaches used in routine diagnostics to detect driver mutations such as EGFR, KRAS, BRAF or MET allows the identification of other alterations that could modulated the intensity or duration of response to targeted therapies. The prevalence of co-occurring alterations that could affect response or prognosis as not been largely analyzed in clinical settings and large cohorts of patients. Thanks to the IFCT program "Biomarkers France", a collection of samples and data at a nation-wide level was available to test the impact of co-mutations on first line EGFR TKI in patients with EGFR mutated cancers. MATERIALS AND METHODS Targeted NGS was assessed on available (n = 208) samples using the Ion AmpliSeq™ Cancer Hotspot Panel v2 to screen for mutations in 50 different cancer genes. RESULTS This study showed that PTEN inactivating mutations, ATM alterations, IDH1 mutations and complex EGFR mutations were predictors of short PFS in patients with a stage 4 lung adenocarcinoma receiving first line EGFR TKI and that PTEN, ATM, IDH1 and KRAS mutations as well as alterations in the MAPK pathway were related to shorter OS. CONCLUSION These findings may lead to new treatment options in patients with unfavorable genotypes to optimize first line responses.
Collapse
Affiliation(s)
- H Blons
- HEGP, Biochimie UF de Pharmacogénétique et Oncologie Moléculaire, Paris, France; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, France
| | - J-B Oudart
- HEGP, Biochimie UF de Pharmacogénétique et Oncologie Moléculaire, Paris, France
| | - J-P Merlio
- Tumor Bank and Tumor Biology Department, CHU Bordeaux, Bordeaux France; INSERM U1053, Univ. Bordeaux, Bordeaux France
| | - D Debieuvre
- Service de pneumologie, GHRMSA-Hôpital Emile Muller, Mulhouse, France
| | - F de Fraipont
- Unité de Génétique Moléculaire, Maladies Héréditaires et Oncologie, CHU Grenoble Alpes, Grenoble, France
| | | | - F Escande
- Laboratoire de Biochimie et Biologie Moléculaire, CHU Lille, France
| | - S Hominal
- Centre Hospitalier Annecy-Genevois, Epagny-Metz Tessy, France
| | - P-P Bringuier
- Institut de Pathologie Multi-Sites des Hospices Civils de Lyon - Site Est, Plateforme de Pathologie Moléculaire, Hospices Civils de Lyon, Lyon, France; Université Claude Bernard Lyon 1, Lyon, France
| | | | - L Ouafik
- Aix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France; APHM, CHU Nord, Service de Transfert d'Oncologie Biologique, Marseille, France
| | - D Moro-Sibilot
- Unité d'Oncologie Thoracique, Service Hospitalier Universitaire Pneumologie Physiologie Pôle Thorax et Vaisseaux, CHU Grenoble Alpes, Grenoble, France
| | - A Lemoine
- Biochimie et Oncogénétique INSERM UMR-S1193, Hôpital Paul Brousse, Hôpitaux Universitaires Paris-Sud, Villejuif, France
| | - A Langlais
- Department of Biostatistics, French Cooperative Thoracic Intergroup, Paris, France
| | - P Missy
- Clinical Research Unit, French Cooperative Thoracic Intergroup, Paris, France
| | - F Morin
- Clinical Research Unit, French Cooperative Thoracic Intergroup, Paris, France
| | - P-J Souquet
- Service de pneumologie aiguë spécialisée et cancérologie thoracique, Hospices Civils de Lyon, Centre hospitalier Lyon-Sud, Pierre-Bénite, France
| | - F Barlesi
- Aix Marseille University, INSERM, CNRS, CRCM, APHM, Multidisciplinary Oncology & Therapeutic Innovations Department, Marseille, France
| | - J Cadranel
- AP-HP, Hôpital Tenon, Service de Pneumogie, GRC 04 Theranoscan, Sorbonne Université, Paris, France
| | - M Beau-Faller
- Laboratory of Biochemistry and Molecular Biology, Centre Hospitalier Universitaire de Strasbourg, Hôpital de Hautepierre, Strasbourg, France; IRFAC UMR-S1113, Inserm, Université de Strasbourg, Strasbourg, France.
| | | |
Collapse
|
9
|
Lemoine A, Tounian P. Childhood anemia and iron deficiency in sub-Saharan Africa – risk factors and prevention: A review. Arch Pediatr 2020; 27:490-496. [DOI: 10.1016/j.arcped.2020.08.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2019] [Revised: 04/15/2020] [Accepted: 08/13/2020] [Indexed: 12/17/2022]
|
10
|
Lemoine A, Van de Velde M, Jacobs A, Joshi G, Bonnet F. PROSPECT review methodology for oncological breast surgery: a reply. Anaesthesia 2020; 76:288-289. [PMID: 33080069 DOI: 10.1111/anae.15284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/22/2020] [Indexed: 11/28/2022]
Affiliation(s)
- A Lemoine
- APHP - Sorbonne Université, Paris, France
| | | | - A Jacobs
- University Hospital, Leuven, Belgium
| | - G Joshi
- University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - F Bonnet
- APHP - Sorbonne Université, Paris, France
| |
Collapse
|
11
|
Lemoine A, Van de Velde M, Jacobs A, Joshi G, Bonnet F. PROSPECT guidelines for oncological breast surgery: the role of non-opioid analgesics, a reply. Anaesthesia 2020; 76:141-142. [PMID: 33015825 DOI: 10.1111/anae.15266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/02/2020] [Indexed: 10/23/2022]
Affiliation(s)
- A Lemoine
- APHP - Sorbonne Université, Paris, France
| | | | - A Jacobs
- University Hospital, Leuven, Belgium
| | - G Joshi
- University of Texas Southwestern Medical Center, Dallas, USA
| | - F Bonnet
- APHP - Sorbonne Université, Paris, France
| |
Collapse
|
12
|
Lemoine A, Pauliat-Desbordes S, Challier P, Tounian P. Adverse reactions to food additives in children: A retrospective study and a prospective survey. Arch Pediatr 2020; 27:368-371. [PMID: 32807620 DOI: 10.1016/j.arcped.2020.07.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Accepted: 07/24/2020] [Indexed: 11/17/2022]
Abstract
BACKGROUND Allergic reactions to food additives are often suspected by families. The aim of this study was to describe oral food challenge (OFC) outcomes in a pediatric cohort with a suspected diagnosis of allergy to food additives (food dyes or sodium benzoate). METHODS All patients who underwent an open OFC to carmine red, cochineal red, erythrosine, patent blue V, tartrazine, yellow sunset S, and/or sodium benzoate were included. A survey was sent to families after testing to evaluate whether the OFC results had altered feeding behaviors with food additives. RESULTS Twenty-three patients were included. The main suspected food was candy (n=11/23; 48%). Only one OFC out of 45 was formally positive for the carmine and cochineal red. Subsequently, most OFCs were negative (44/45; 97.8%). Despite the negativity of the challenge, four families out of 14 reported occurrences of supposed allergic reactions to food additives and six out of 15 continued to completely avoid the additive of concern in their children's diet. CONCLUSIONS Allergies to food additives remain rare. Even if an IgE-mediated allergy was excluded with a negative OFC, families remained suspicious about ready-made products. Health professionals and parents should be reassured about the low risk of food dye intolerance or allergies.
Collapse
Affiliation(s)
- A Lemoine
- Department of Paediatric Nutrition and Gastroenterology, Trousseau Hospital, AP-HP, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France; Sorbonne Université, 21, rue de l'École-de-Médecine, 75006 Paris, France.
| | - S Pauliat-Desbordes
- Department of Paediatric Nutrition and Gastroenterology, Trousseau Hospital, AP-HP, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France
| | - P Challier
- Department of Paediatric Nutrition and Gastroenterology, Trousseau Hospital, AP-HP, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France
| | - P Tounian
- Department of Paediatric Nutrition and Gastroenterology, Trousseau Hospital, AP-HP, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France; Sorbonne Université, 21, rue de l'École-de-Médecine, 75006 Paris, France
| |
Collapse
|
13
|
Lemoine A, Van de Velde M, Jacobs A, Joshi G, Bonnet F. Breast surgery analgesia: a reply. Anaesthesia 2020; 75:1406-1407. [PMID: 32654117 DOI: 10.1111/anae.15192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/12/2020] [Indexed: 11/28/2022]
Affiliation(s)
- A Lemoine
- APHP - Sorbonne Université, Paris, France
| | | | - A Jacobs
- University Hospital, Leuven, Belgium
| | - G Joshi
- University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - F Bonnet
- APHP - Sorbonne Université, Paris, France
| |
Collapse
|
14
|
Jacobs A, Lemoine A, Joshi GP, Van de Velde M, Bonnet F. PROSPECT guideline for oncological breast surgery: a systematic review and procedure-specific postoperative pain management recommendations. Anaesthesia 2020; 75:664-673. [PMID: 31984479 PMCID: PMC7187257 DOI: 10.1111/anae.14964] [Citation(s) in RCA: 95] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/27/2019] [Indexed: 12/17/2022]
Abstract
Analgesic protocols used to treat pain after breast surgery vary significantly. The aim of this systematic review was to evaluate the available literature on this topic and develop recommendations for optimal pain management after oncological breast surgery. A systematic review using preferred reporting items for systematic reviews and meta-analysis guidance with procedure-specific postoperative pain management (PROSPECT) methodology was undertaken. Randomised controlled trials assessing postoperative pain using analgesic, anaesthetic or surgical interventions were identified. Seven hundred and forty-nine studies were found, of which 53 randomised controlled trials and nine meta-analyses met the inclusion criteria and were included in this review. Quantitative analysis suggests that dexamethasone and gabapentin reduced postoperative pain. The use of paravertebral blocks also reduced postoperative pain scores, analgesia consumption and the incidence of postoperative nausea and vomiting. Intra-operative opioid requirements were documented to be lower when a pectoral nerves block was performed, which also reduced postoperative pain scores and opioid consumption. We recommend basic analgesics (i.e. paracetamol and non-steroidal anti-inflammatory drugs) administered pre-operatively or intra-operatively and continued postoperatively. In addition, pre-operative gabapentin and dexamethasone are also recommended. In major breast surgery, a regional anaesthetic technique such as paravertebral block or pectoral nerves block and/or local anaesthetic wound infiltration may be considered for additional pain relief. Paravertebral block may be continued postoperatively using catheter techniques. Opioids should be reserved as rescue analgesics in the postoperative period. Research is needed to evaluate the role of novel regional analgesic techniques such as erector spinae plane or retrolaminar plane blocks combined with basic analgesics in an enhanced recovery setting.
Collapse
Affiliation(s)
- A. Jacobs
- Department of Cardiovascular SciencesKULeuven and University Hospital LeuvenLeuvenBelgium
| | - A. Lemoine
- Service d'Anesthésie – Réanimation et Médecine Péri‐opératoireHopital TenonAPHPParis, France/Médecine‐Sorbonne UniversitéParisFrance
| | - G. P. Joshi
- Department of Anesthesiology and Pain ManagementUniversity of Texas Southwestern Medical CenterDallasTXUSA
| | - M. Van de Velde
- Department of Cardiovascular SciencesKULeuven and University Hospital LeuvenLeuvenBelgium
| | - F. Bonnet
- Service d'Anesthésie – Réanimation et Médecine Péri‐opératoireHopital TenonAPHPParis, France/Médecine‐Sorbonne UniversitéParisFrance
| |
Collapse
|
15
|
Lemoine A, Giabicani E, Lockhart V, Grimprel E, Tounian P. Case report of nutritional rickets in an infant following a vegan diet. Arch Pediatr 2020; 27:219-222. [PMID: 32334899 DOI: 10.1016/j.arcped.2020.03.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2019] [Revised: 02/19/2020] [Accepted: 03/28/2020] [Indexed: 01/24/2023]
Abstract
We report the case of a 13-month-old infant who was referred to the pediatric emergency department because of psychomotor regression with four bone fractures due to nutritional rickets. The reason was prolonged breastfeeding from a vegetarian mother followed by a vegan diet for the infant after weaning. Rickets is one of the many nutritional deficiencies that could affect infants fed vegan or vegetarian diets. These diets are a public health concern requiring adapted information that suggests alternative formulas made from rice or soy proteins and adapted supplementation after weaning.
Collapse
Affiliation(s)
- A Lemoine
- Paediatric Nutrition and Gastroenterology Department, Trousseau Hospital-AP-HP, Sorbonne Université, 26, avenue du Dr Arnold-Netter, 75012 Paris, France.
| | - E Giabicani
- Sorbonne Université, INSERM, Centre de Recherche Saint Antoine, APHP, Hôpital Armand Trousseau, Explorations Fonctionnelles Endocriniennes, 75012, Paris, France
| | - V Lockhart
- Sorbonne Université, INSERM, Centre de Recherche Saint Antoine, APHP, Hôpital Armand Trousseau, Explorations Fonctionnelles Endocriniennes, 75012, Paris, France
| | - E Grimprel
- Department of Paediatrics, Trousseau Hospital-AP-HP; Sorbonne Université, 75012 Paris, France
| | - P Tounian
- Paediatric Nutrition and Gastroenterology Department, Trousseau Hospital-AP-HP, Sorbonne Université, 26, avenue du Dr Arnold-Netter, 75012 Paris, France
| |
Collapse
|
16
|
El kaddouri H, Doerfler A, Broeders N, Nortier J, Lemoine A, Quackels T, Roumeguère T. Cancer de la vessie et transplantation rénale. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
17
|
Bouchahda M, Karaboué A, Saffroy R, Hamelin J, Bosselut N, Lemoine A. Undetectable RAS mutant clones in plasma: Possible implication for therapy and prognosis in the patient with RAS mutant metastatic colorectal cancer? Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze P, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la motte rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda M, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E. Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up). J Gynecol Obstet Hum Reprod 2019; 48:379-386. [DOI: 10.1016/j.jogoh.2019.03.018] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2019] [Accepted: 03/19/2019] [Indexed: 10/27/2022]
|
19
|
Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Long text of the Joint French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Part 1: Diagnostic exploration and staging, surgery, perioperative care, and pathology. J Gynecol Obstet Hum Reprod 2019; 48:369-378. [PMID: 30936027 DOI: 10.1016/j.jogoh.2019.03.017] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2019] [Accepted: 03/19/2019] [Indexed: 11/27/2022]
Abstract
An MRI is recommended for an ovarian mass that is indeterminate on ultrasound. The ROMA score (combining CA125 and HE4) can also be calculated (grade A). In presumed early-stage ovarian or tubal cancers, the following procedures should be performed: an omentectomy (at a minimum, infracolic), an appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C), and pelvic and para-aortic lymphadenectomies (grade B) for all histologic types, except the expansile mucinous subtypes, for which lymphadenectomies can be omitted (grade C). Minimally invasive surgery is recommended for early-stage ovarian cancer, when there is no risk of tumor rupture (grade B). For FIGO stages III or IV ovarian, tubal, and primary peritoneal cancers, a contrast-enhanced computed tomography (CT) scan of the thorax/abdomen/pelvis is recommended (grade B), as well as laparoscopic exploration to take multiple biopsies (grade A) and a carcinomatosis score (Fagotti score at a minimum) (grade C) to assess the possibility of complete surgery (i.e., leaving no macroscopic tumor residue). Complete surgery by a midline laparotomy is recommended for advanced ovarian, tubal, or primary peritoneal cancer (grade B). For advanced cancers, para-aortic and pelvic lymphadenectomies are recommended when metastatic adenopathy is clinically or radiologically suspected (grade B). When adenopathy is not suspected and when complete peritoneal surgery is performed as the initial surgery for advanced cancer, the lymphadenectomies can be omitted because they do not modify either the medical treatment or overall survival (grade B). Primary surgery (before other treatment) is recommended whenever it appears possible to leave no tumor residue (grade B).
Collapse
Affiliation(s)
- V Lavoue
- Service de gynécologie, CHU de Rennes, Hôpital sud, 16 Bd de Bulgarie, 35000 Rennes, France; INSERM 1242, Chemistry, Oncogenesis, Stress and Signaling, Centre Eugène Marquis, Rue Bataille Flandres-Dunkerques, Rennes, France.
| | - C Huchon
- Service de Gynécologie, CHI Poissy, France
| | - C Akladios
- Service de Gynécologie, Hôpital Hautepierre, CHU Strasbourg, France
| | - P Alfonsi
- Service d'Anesthésie, Hôpital Saint Joseph, Paris, France
| | - N Bakrin
- Service de chirurgie digestive, CHU Lyon-Sud, Pierre-Bénite, Lyon, France
| | - M Ballester
- Service de gynécologie, GH Diaconesses Croix Saint Simon, Paris, France
| | - S Bendifallah
- Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Hôpital Tenon, 4 rue de La Chine, APHP, Institut Universitaire de Cancérologie Sorbonne Université, UMRS-938, France
| | - P A Bolze
- Service de chirurgie gynécologique, CHU Lyon-Sud, Pierre Bénite, Lyon, France
| | - F Bonnet
- Service d'anesthésie, Hôpital Tenon, AP-HP, Paris, France
| | - C Bourgin
- Service de Chirurgie Gynécologique, Hôpital Jeanne de Flandres, CHRU, Lille, France
| | - N Chabbert-Buffet
- Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Hôpital Tenon, 4 rue de La Chine, APHP, Institut Universitaire de Cancérologie Sorbonne Université, UMRS-938, France
| | - P Collinet
- Service de Chirurgie Gynécologique, Hôpital Jeanne de Flandres, CHRU, Lille, France
| | - B Courbiere
- Pôle Femmes-Parents-Enfants - Centre Clinico-Biologique d'AMP, AP-HM La Conception, 147 bd Baille, 13005 Marseille/Aix Marseille Université, CNRS, IRD, Avignon Université, IMBE UMR 7263, 13397 Marseille, France
| | | | | | - C Falandry
- Service d'oncogériatrie, Hospices civiles de Lyon, CHU Lyon-Sud, Pierre-Bénite, Lyon, France
| | - G Ferron
- Service d'oncologie chirurgicale, Institut Claudius Regaud, IUCT Oncopole, Toulouse, France
| | - L Fournier
- Service de radiologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France
| | - L Gladieff
- Service d'oncologie médicale, Institut Claudius Regaud, IUCT Oncopole, Toulouse, France
| | - F Golfier
- Service de chirurgie gynécologique, CHU Lyon-Sud, Pierre Bénite, Lyon, France
| | - S Gouy
- Service de chirurgie, Institut Gustave Roussy, Villejuif, France
| | - F Guyon
- Service de chirurgie, Institut Bergonié, Bordeaux, France
| | - E Lambaudie
- Service de chirurgie, Institut Paoli Calmette, Marseille, France
| | - A Leary
- Service d'oncologie médicale, Institut Gustave Roussy, Villejuif, France
| | - F Lecuru
- Service de chirurgie gynécologique et oncologique, Hôpital Européen Georges Pompidou, AP-HP, Paris, France
| | - M A Lefrere-Belda
- Service d'anatomo-pathologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France
| | - E Leblanc
- Service de chirurgie, Centre Oscar Lambret, Lille, France
| | - A Lemoine
- Service d'anesthésie, Hôpital Tenon, AP-HP, Paris, France
| | - F Narducci
- Service de chirurgie, Centre Oscar Lambret, Lille, France
| | - L Ouldamer
- Service de chirurgie gynécologique, CHU de Tours, France
| | - P Pautier
- Service d'oncologie médicale, Institut Gustave Roussy, Villejuif, France
| | - F Planchamp
- Service de méthodologie, Institut Bergonié, Bordeaux, France
| | - N Pouget
- Service de chirurgie, Curie (site Saint Cloud), Paris, France
| | - I Ray-Coquard
- Service d'oncologie médicale, Centre Léon Bérard, Lyon, France
| | | | | | - C Touboul
- Service de chirurgie gynécologique, CHI de Créteil, Créteil, France
| | | | - C Uzan
- Service de chirurgie et cancérologie gynécologique et mammaire, Hôpital Pitié Salpêtrière, Institut Universitaire de Cancérologie, Sorbonne Université, INSERM U938, France
| | - B You
- Service d'oncologie médicale, Institut de cancérologie des Hospices Civils de Lyon, Pierre-Bénite, Lyon, Paris, France
| | - E Daraï
- Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Hôpital Tenon, 4 rue de La Chine, APHP, Institut Universitaire de Cancérologie Sorbonne Université, UMRS-938, France
| |
Collapse
|
20
|
Lemoine A, Mamann N, Larroquet M, Tounian P, Irtan S, Lemale J. Ingestion of neodymium magnet spheres: Three case studies. Arch Pediatr 2019; 26:179-181. [PMID: 30827774 DOI: 10.1016/j.arcped.2019.02.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2018] [Revised: 09/10/2018] [Accepted: 02/03/2019] [Indexed: 11/25/2022]
Abstract
We report three pediatric cases of two, five, and 12 neodymium magnet spheres ingested simultaneously. In two cases, endoscopic extraction failed because of the strength of the magnetic attraction and a gastrotomy was performed to remove all magnets. In the third case, the magnets were not accessible endoscopically and were removed by laparotomy. We wish to warn consumer groups and pediatricians about the danger of neodymium magnets.
Collapse
Affiliation(s)
- A Lemoine
- Pediatric Nutrition and Gastroenterology Department, Trousseau Hospital, AP-HP, 26, avenue du Dr Arnold-Netter, 75012 Paris, France; Sorbonne université, faculté de médecine, 91, boulevard de l'hôpital, 75013 Paris, France.
| | - N Mamann
- Pediatric Nutrition and Gastroenterology Department, Trousseau Hospital, AP-HP, 26, avenue du Dr Arnold-Netter, 75012 Paris, France; Sorbonne université, faculté de médecine, 91, boulevard de l'hôpital, 75013 Paris, France
| | - M Larroquet
- Department of Pediatric Surgery, Trousseau Hospital, AP-HP, 26, avenue du Dr Arnold-Netter, 75012 Paris, France
| | - P Tounian
- Pediatric Nutrition and Gastroenterology Department, Trousseau Hospital, AP-HP, 26, avenue du Dr Arnold-Netter, 75012 Paris, France
| | - S Irtan
- Department of Pediatric Surgery, Trousseau Hospital, AP-HP, 26, avenue du Dr Arnold-Netter, 75012 Paris, France; Sorbonne université, faculté de médecine, 91, boulevard de l'hôpital, 75013 Paris, France
| | - J Lemale
- Pediatric Nutrition and Gastroenterology Department, Trousseau Hospital, AP-HP, 26, avenue du Dr Arnold-Netter, 75012 Paris, France; Sorbonne université, faculté de médecine, 91, boulevard de l'hôpital, 75013 Paris, France
| |
Collapse
|
21
|
Lemoine A, Aroulandom J, O’Neill C, Lemale J, Tounian P. Les suspicions d’allergies au lait de vache non IgE-médiée sont rarement confirmées. NUTR CLIN METAB 2019. [DOI: 10.1016/j.nupar.2019.01.399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
22
|
Lavoué V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lécuru F, Lefrère-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Sénéchal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E. [Part II drafted from the short text of the French guidelines entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. (Systemic and intraperitoneal treatment, elderly, fertility preservation, follow-up)]. ACTA ACUST UNITED AC 2019; 47:111-119. [PMID: 30704955 DOI: 10.1016/j.gofs.2018.12.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2018] [Indexed: 10/27/2022]
Abstract
Adjuvant chemotherapy with carboplatin and paclitaxel is recommended for all high-grade ovarian or Fallopian tube cancers, stage FIGO I-IIA (grade A). After a complete first surgery, it is recommended to deliver 6 cycles of intravenous (grade A) or to propose intraperitoneal (grade B) chemotherapy, to be discussed with patient, according to the benefit/risk ratio. After a complete interval surgery for a FIGO III stage, the hyperthermic intra peritoneal chemotherapy (HIPEC) can be proposed in the same conditions of the OV-HIPEC trial (grade B). In case of tumor residue after surgery or FIGO stage IV, chemotherapy associated with bevacizumab is recommended (grade A). For BRCA mutated patient, Olaparib is recommended (grade B).
Collapse
Affiliation(s)
- V Lavoué
- Service de gynécologie, hôpital sud, CHU de Rennes, 16, boulevard de Bulgarie, 35000 Rennes, France; Inserm 1242, chemistry, oncogenesis, stress and signaling, centre Eugène-Marquis, rue Bataille-Flandres-Dunkerques, 35000 Rennes, France.
| | - C Huchon
- Service de gynécologie, CHI Poissy, 78000 Poissy, France
| | - C Akladios
- Service de gynécologie, hôpital Hautepierre, CHU de Strasbourg, 67000 Strasbourg, France
| | - P Alfonsi
- Service d'anesthésie, hôpital Saint-Joseph, 75014 Paris, France
| | - N Bakrin
- Service de chirurgie digestive, CHU Lyon-Sud, Pierre-Bénite, 69000 Lyon, France
| | - M Ballester
- Service de gynécologie, groupe hospitalier Diaconesses-Croix-Saint-Simon, 75020 Paris, France
| | - S Bendifallah
- Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Institut universitaire de cancérologie, UMRS-938, Sorbonne université, 75000 Paris, France
| | - P A Bolze
- Service de chirurgie gynécologique, CHU Lyon-Sud, Pierre-Bénite, 69000 Lyon, France
| | - F Bonnet
- Service d'anesthésie, hôpital Tenon, AP-HP, 75020 Paris, France
| | - C Bourgin
- Service de chirurgie gynécologique, hôpital Jeanne-de-Flandres, CHRU de Lille, 59000 Lille, France
| | - N Chabbert-Buffet
- Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Institut universitaire de cancérologie, UMRS-938, Sorbonne université, 75000 Paris, France
| | - P Collinet
- Service de chirurgie gynécologique, hôpital Jeanne-de-Flandres, CHRU de Lille, 59000 Lille, France
| | - B Courbiere
- Pôle Femmes-Parents-Enfants, centre clinico-biologique d'AMP, AP-HM La Conception, 147, boulevard Baille, 13005 Marseille, France; CNRS, IRD, IMBE UMR 7263, Avignon université, Aix Marseille université, 13397 Marseille, France
| | | | - M Devouassoux-Shisheboran
- Service d'anatomo-pathologie, hospices civiles de Lyon, CHU Lyon-Sud, Pierre-Bénite, 69000 Lyon, France
| | - C Falandry
- Service d'oncogériatrie, hospices civiles de Lyon, CHU Lyon-Sud, Pierre-Bénite, 69000 Lyon, France
| | - G Ferron
- Service d'oncologie chirurgicale, institut Claudius-Regaud, IUCT Oncopole, 31000 Toulouse, France
| | - L Fournier
- Service de radiologie, hôpital européen Georges-Pompidou, AP-HP, 75015 Paris, France
| | - L Gladieff
- Service d'oncologie médicale, institut Claudius-Regaud, IUCT Oncopole, 31000 Toulouse, France
| | - F Golfier
- Service de chirurgie gynécologique, CHU Lyon-Sud, Pierre-Bénite, 69000 Lyon, France
| | - S Gouy
- Service de chirurgie, institut Gustave-Roussy, 94000 Villejuif, France
| | - F Guyon
- Service de chirurgie, institut Bergonié, 33000 Bordeaux, France
| | - E Lambaudie
- Service de chirurgie, institut Paoli-Calmette, 13000 Marseille, France
| | - A Leary
- Service d'oncologie médicale, institut Gustave-Roussy, 94000 Villejuif, France
| | - F Lécuru
- Service de chirurgie gynécologique et oncologique, hôpital européen Georges-Pompidou, AP-HP, 75015 Paris, France
| | - M A Lefrère-Belda
- Service d'anatomo-pathologie, hôpital européen Georges-Pompidou, AP-HP, 75015 Paris, France
| | - E Leblanc
- Service de chirurgie, centre Oscar-Lambret, 59000 Lille, France
| | - A Lemoine
- Service d'anesthésie, hôpital Tenon, AP-HP, 75020 Paris, France
| | - F Narducci
- Service de chirurgie, centre Oscar-Lambret, 59000 Lille, France
| | - L Ouldamer
- Service de chirurgie gynécologique, CHU de Tours, 37000 Tours, France
| | - P Pautier
- Service d'oncologie médicale, institut Gustave-Roussy, 94000 Villejuif, France
| | - F Planchamp
- Service de méthodologie, institut Bergonié, 33000 Bordeaux, France
| | - N Pouget
- Service de chirurgie, Curie (site Saint-Cloud), 75000 Paris, France
| | - I Ray-Coquard
- Service d'oncologie médicale, centre Léon-Bérard, 69000 Lyon, France
| | | | | | - C Touboul
- Service de chirurgie gynécologique, CHI de Créteil, 94000 Créteil, France
| | | | - C Uzan
- Service de chirurgie et cancérologie gynécologique et mammaire, hôpital Pitié-Salpêtrière, 75013 Paris, France; Inserm U938, institut universitaire de cancérologie, Sorbonne université, 75000 Paris, France
| | - B You
- Service d'oncologie médicale, institut de cancérologie, hospices civils de Lyon, Pierre-Bénite, 69000 Lyon, France
| | - E Daraï
- Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Institut universitaire de cancérologie, UMRS-938, Sorbonne université, 75000 Paris, France
| |
Collapse
|
23
|
Lavoué V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lécuru F, Lefrère-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Sénéchal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E. [Part I drafted from the short text of the French Guidelines entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. (Diagnosis management, surgery, perioperative care, and pathological analysis)]. ACTA ACUST UNITED AC 2019; 47:100-110. [PMID: 30686724 DOI: 10.1016/j.gofs.2018.12.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2018] [Indexed: 10/27/2022]
Abstract
Faced to an undetermined ovarian mass on ultrasound, an MRI is recommended and the ROMA score (combining CA125 and HE4) can be proposed (grade A). In case of suspected early stage ovarian or fallopian tube cancer, omentectomy (at least infracolonic), appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C) and pelvic and para-aortic lymphadenectomy are recommended (grade B) for all histological types, except for the expansive mucinous subtype where lymphadenectomy may be omitted (grade C). Minimally invasive surgery is recommended for early stage ovarian cancer, if there is no risk of tumor rupture (grade B). Laparoscopic exploration for multiple biopsies (grade A) and to evaluate carcinomatosis score (at least using the Fagotti score) (grade C) are recommended to estimate the possibility of a complete surgery (i.e. no macroscopic residue). Complete medial laparotomy surgery is recommended for advanced cancers (grade B). It is recommended in advanced cancers to perform para-aortic and pelvic lymphadenectomy in case of clinical or radiological suspicion of metastatic lymph node (grade B). In the absence of clinical or radiological lymphadenopathy and in case of complete peritoneal surgery during an initial surgery for advanced cancer, it is possible not to perform a lymphadenectomy because it does not modify the medical treatment and the overall survival (grade B). Primary surgery is recommended when no tumor residue is possible (grade B).
Collapse
Affiliation(s)
- V Lavoué
- Service de gynécologie, hôpital sud, CHU de Rennes, 16, boulevard de Bulgarie, 35000 Rennes, France; Inserm 1242, Chemistry, Oncogenesis, Stress and Signaling, Centre Eugène Marquis, rue Bataille Flandres-Dunkerques, 35000 Rennes, France.
| | - C Huchon
- Service de gynécologie, CHI Poissy, 78000 Poissy, France
| | - C Akladios
- Service de gynécologie, hôpital Hautepierre, CHU Strasbourg, 67000 Strasbourg, France
| | - P Alfonsi
- Service d'anesthésie, hôpital Saint-Joseph, 75014 Paris, France
| | - N Bakrin
- Service de chirurgie digestive, CHU Lyon-Sud, Pierre-Bénite, 69000 Lyon, France
| | - M Ballester
- Service de gynécologie, groupe hospitalier Diaconesses Croix Saint Simon, 75020 Paris, France
| | - S Bendifallah
- Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; UMRS-938, institut universitaire de cancérologie Sorbonne université, 75000 Paris, France
| | - P A Bolze
- Service de chirurgie gynécologique, CHU Lyon-Sud, Pierre-Bénite, 69000 Lyon, France
| | - F Bonnet
- Service d'anesthésie, hôpital Tenon, AP-HP, 75020 Paris, France
| | - C Bourgin
- Service de chirurgie gynécologique, hôpital Jeanne de Flandres, CHRU, 59000 Lille, France
| | - N Chabbert-Buffet
- Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; UMRS-938, institut universitaire de cancérologie Sorbonne université, 75000 Paris, France
| | - P Collinet
- Service de chirurgie gynécologique, hôpital Jeanne de Flandres, CHRU, 59000 Lille, France
| | - B Courbiere
- Pôle Femmes-Parents-Enfants-Centre Clinico-Biologique d'AMP, AP-HM La Conception, 147, boulevard Baille, 13005 Marseille, France; IMBE UMR 7263, Aix-Marseille université, CNRS, IRD, Avignon université, 13397 Marseille, France
| | | | - M Devouassoux-Shisheboran
- Service d'anatomopathologie, hospices civiles de Lyon, CHU Lyon-Sud, Pierre-Bénite, 69000 Lyon, France
| | - C Falandry
- Service d'oncogériatrie, hospices civiles de Lyon, CHU Lyon-Sud, Pierre-Bénite, 69000 Lyon, France
| | - G Ferron
- Service d'oncologie chirurgicale, institut Claudius Regaud, IUCT Oncopole, 31000 Toulouse, France
| | - L Fournier
- Service de radiologie, hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France
| | - L Gladieff
- Service d'oncologie médicale, institut Claudius Regaud, IUCT Oncopole, 31000 Toulouse, France
| | - F Golfier
- Service de chirurgie gynécologique, CHU Lyon-Sud, Pierre-Bénite, 69000 Lyon, France
| | - S Gouy
- Service de chirurgie, institut Gustave Roussy, 94000 Villejuif, France
| | - F Guyon
- Service de chirurgie, institut Bergonié, 33000 Bordeaux, France
| | - E Lambaudie
- Service de chirurgie, institut Paoli Calmette, 13000 Marseille, France
| | - A Leary
- Service d'oncologie médicale, institut Gustave Roussy, 94000 Villejuif, France
| | - F Lécuru
- Service de chirurgie gynécologique et oncologique, hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France
| | - M A Lefrère-Belda
- Service d'anatomopathologie, hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France
| | - E Leblanc
- Service de chirurgie, Centre Oscar Lambret, 59000 Lille, France
| | - A Lemoine
- Service d'anesthésie, hôpital Tenon, AP-HP, 75020 Paris, France
| | - F Narducci
- Service de chirurgie, Centre Oscar Lambret, 59000 Lille, France
| | - L Ouldamer
- Service de chirurgie gynécologique, CHU de Tours, 37000 Tours, France
| | - P Pautier
- Service d'oncologie médicale, institut Gustave Roussy, 94000 Villejuif, France
| | - F Planchamp
- Service de méthodologie, institut Bergonié, 33000 Bordeaux, France
| | - N Pouget
- Service de chirurgie, Curie (site Saint Cloud), 75000 Paris, France
| | - I Ray-Coquard
- Service d'oncologie médicale, Centre Léon Bérard, 69000 Lyon, France
| | | | | | - C Touboul
- Service de chirurgie gynécologique, CHI de Créteil, 94000 Créteil, France
| | | | - C Uzan
- Service de chirurgie et cancérologie gynécologique et mammaire, hôpital Pitié-Salpêtrière, 75013 Paris, France; Inserm U938, institut universitaire de cancérologie, Sorbonne université, 75000 Paris, France
| | - B You
- Service d'oncologie médicale, institut de cancérologie des hospices Civils de Lyon, Pierre-Bénite, 69000 Lyon Paris, France
| | - E Daraï
- Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; UMRS-938, institut universitaire de cancérologie Sorbonne université, 75000 Paris, France
| |
Collapse
|
24
|
Lemoine A, Lambaudie E, Bonnet F, Leblanc E, Alfonsi P. [Perioperative care of epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa]. ACTA ACUST UNITED AC 2019; 47:187-196. [PMID: 30686730 DOI: 10.1016/j.gofs.2018.12.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2018] [Indexed: 01/28/2023]
Abstract
The following recommendations cover the perioperative management of ovarian, Fallopian tube and primary peritoneal cancers. Five questions related to pre-habilitation and enhanced recovery after surgery were evaluated. The conclusions and recommendations are based on an analysis of the level of evidence available in the literature. These recommendations are part of the overall recommendations for improving the management of ovarian, fallopian or primary peritoneal cancer, made with the support of INCa (Institut National du Cancer). The main preoperative measures are screening for nutritional deficiencies (Grade B) and for anaemia (GradeC) in patients with ovarian cancer. It is not possible to make recommendations on the correction of malnutrition and/or anemia or on the contribution of pre-operative immuno-nutrition due to the absence of data in ovarian cancer, tube cancer or primary peritoneum cancer. For the same reasons, no recommendation can be made on the value of preoperative digestive preparation in ovarian, fallopian tube or primary peritoneum cancer. During surgery, goal-directed fluid therapy for patients with advanced ovarian cancer is recommended (Grade B). A single dose infusion of tranexamic acid is recommended for patients with ovarian, fallopian tube or primary peritoneal cancer (GradeC). For postoperative analgesia, epidural analgesia is recommended for patients undergoing cyto-reduction surgery by laparotomy (Grade B). In the absence of epidural analgesia, patient controlled analgesia with morphine without continuous infusion (Grade B) is recommended. No recommendation can be given regarding intravenous administration of lidocaine and/or ketamine during surgery, or, regarding peri-operatively prescription of gabapentin or pregabalin. In the absence of studies on the impact of different non-opiate analgesic combinations for ovarian cancer surgery, no recommendations can be made. Early oral feeding is recommended, including in cases of digestive resection (Grade B). The implementation of enhanced recovery programs, including early mobilization, is recommended (GradeC).
Collapse
Affiliation(s)
- A Lemoine
- Service d'anesthésie, hôpital Tenon, médecine Sorbonne université, 75020 Paris, France.
| | - E Lambaudie
- Inserm, département de chirurgie oncologique, institut Paoli Calmettes, Aix-Marseille université, CNRS, 13000 Marseille, France
| | - F Bonnet
- Service d'anesthésie, hôpital Tenon, médecine Sorbonne université, 75020 Paris, France
| | - E Leblanc
- Département de chirurgie oncologique, centre Oscar Lambret, 59000 Lille, France
| | - P Alfonsi
- Service d'anesthésie, université Paris Descartes, groupe hospitalier Paris Saint-Joseph, 75014 Paris, France
| |
Collapse
|
25
|
Lemoine A, Tounian P. Allergie aux colorants alimentaires : une pathologie à évoquer avec parcimonie. Revue Française d'Allergologie 2018. [DOI: 10.1016/j.reval.2018.09.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
26
|
Blons H, Oudart JB, Merlio JP, Hominal S, de Fraipont F, Debieuvre D, Escande F, Audigier Valette C, Bringuier PP, Moreau Fraboulet S, Ouafik L, Moro-Sibilot D, Lemoine A, Langlais A, Missy P, Morin F, Souquet PJ, Barlesi F, Cadranel J, Beau-Faller M. Molecular heterogeneity assessment by NGS in non-small cell lung cancer (NSCLC) harboring EGFR mutations: Results of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.123] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Pecuchet N, Touachi R, Ben Lakhdar A, Fallet V, Rabbe N, Blons H, Lemoine A, Antoine M, Tenam S, Laurent-Puig P, Wislez M. Joined analysis of sarcomatoid carcinoma (SC) mutational profiles: Comparison of lung versus head and neck cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy304.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
28
|
Fallet V, Taouachi R, Saffroy R, Ben Lakhdar A, Rabbe N, André F, Temam S, Lemoine A, Wislez M. Head and neck (HN) primary sarcomatoid carcinoma (PSC) profile by high-throughput somatic mutation profiling. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Crespel C, Brami C, de Boissieu P, Mazza C, Chauvet K, Lemoine A, Gavlak B, Léandri C, Brasseur M, Bertin E, Bouché O. [Evaluation of the feasibility of a program of adapted physical activity in day hospital of digestive oncology: From the point of view of patients]. Bull Cancer 2018; 105:228-233. [PMID: 29426740 DOI: 10.1016/j.bulcan.2017.11.011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Revised: 10/22/2017] [Accepted: 11/08/2017] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Adapted physical activity (APA) is recognized as an effective supportive care for asthenia and quality of life in oncology. Before an APA program was organized, the feasibility of such a program was evaluated among the patients. METHODS Descriptive, prospective, semi-qualitative, single-center study over a 3-month period in patients treated with ambulatory chemotherapy for digestive cancer. A self-questionnaire was offered to all patients to evaluate their practice and knowledge about APA. In ten patients, fatigue, anxiety and depression were assessed, before and after 9 weeks of hospital-based APA. The scores were compared by matched Student test. RESULTS Of the 123 patients treated, 80 questionnaires (65%) were exploitable. Before the diagnosis of cancer, 40 patients (50%) were physically active, 20% after (n=16). The reasons for not practicing were: lack of interest/not the idea (42%), lack of time (34%), do not believe in profit (9%), too expensive (8%). Fifty-three patients (66%) were interested in the program. In 10 patients, the APA program significantly reduced the depression score (P=0.024) and a non-significant improvement in anxiety and fatigue. DISCUSSION This study shows that patients treated with chemotherapy are unaware of the usefulness of APA and that medical information can improve adherence to such a program. The establishment of an intra-hospital APA program proved to be possible and relevant.
Collapse
Affiliation(s)
- Céline Crespel
- CHU de Reims, department of gastroenterology, avenue du General-Koenig, 51092 Reims cedex, France
| | - Cloé Brami
- CHU de Reims, department of gastroenterology, avenue du General-Koenig, 51092 Reims cedex, France
| | - Paul de Boissieu
- CHU de Reims, department of research and innovation, avenue du General-Koenig, 51092 Reims cedex, France
| | - Camille Mazza
- CHU de Reims, department of gastroenterology, avenue du General-Koenig, 51092 Reims cedex, France
| | - Kevin Chauvet
- CHU de Reims, department of gastroenterology, avenue du General-Koenig, 51092 Reims cedex, France
| | - Amélie Lemoine
- CHU de Reims, department of gastroenterology, avenue du General-Koenig, 51092 Reims cedex, France
| | - Benoit Gavlak
- CHU de Reims, department of gastroenterology, avenue du General-Koenig, 51092 Reims cedex, France
| | - Chloé Léandri
- CHU de Reims, department of gastroenterology, avenue du General-Koenig, 51092 Reims cedex, France
| | - Mathilde Brasseur
- CHU de Reims, department of gastroenterology, avenue du General-Koenig, 51092 Reims cedex, France
| | - Eric Bertin
- CHU de Reims, department of nutrition, avenue du General-Koenig, 51092 Reims cedex, France
| | - Olivier Bouché
- CHU de Reims, department of gastroenterology, avenue du General-Koenig, 51092 Reims cedex, France.
| |
Collapse
|
30
|
Leduc C, Pencreach E, Merlio J, Bringuier P, De Fraipont F, Escande F, Lemoine A, Ouafik L, Blons H, Denis M, Hofman P, Lacave R, Melaabi S, Langlais A, Missy P, Morin F, Barlesi F, Moro-Sibilot D, Cadranel J, Beau-Faller M. Détection de la mutation T790 M par PCR digitale dans une population de cancers bronchiques non à petites cellules (CBNPC) mutés EGFR, avant le traitement par ITK-EGFR : résultats d’une étude ancillaire à l’étude IFCT Biomarqueurs – France. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Wislez M, Beau-Faller M, Debieuvre D, Ouafik L, Westeel V, Rouquette I, Mazières J, Bringier P, Monnet I, Escande F, Léna H, Merlio J, Jeanicot H, Lemoine A, Foucher P, Poudenx M, Missy P, Langlais A, Souquet P, Barlesi F. Détermination de la valeur pronostique et prédictive de K-RAS à partir de la cohorte de CBNPC Biomarqueurs France. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
32
|
Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, Pouessel D, Mosser J, Vaylet F, Langlais A, Missy P, Morin F, Moro-Sibilot D, Cadranel J, Barlesi F, Beau-Faller M. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol 2017; 28:2715-2724. [PMID: 28945865 DOI: 10.1093/annonc/mdx404] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND EGFR mutations cause inconsistent response to EGFR tyrosine-kinase inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR-mutated non-small-cell lung cancer collected in the Biomarkers France database. PATIENTS AND METHODS Of 17 664 patients, 1837 (11%) with EGFR-mutated non-small-cell lung cancer were retrospectively analyzed for clinical and molecular characteristics. Results were correlated with survival and treatment response for the 848 stage IV patients. RESULTS EGFR exon 18, 19, 20 and 21 mutations were found in 102 (5.5%), 931 (51%), 102 (5.5%) and 702 (38%) patients, respectively. Over 50% of exon 18 and 20 mutated patients were smokers. The median follow-up was 51.7 months. EGFR mutation type was prognostic of overall survival (OS) versus wild-type {exon 19: hazard ratio (HR)=0.51 [95% confidence interval (CI): 0.41-0.64], P < 0.0001; exon 21: HR = 0.76 (95% CI: 0.61-0.95), P = 0.002; exon 20: HR = 1.56 (95% CI: 1.02-2.38), P = 0.004}. EGFR mutation type was prognostic of progression-free survival versus wild-type [exon 19: HR = 0.62 (95% CI: 0.49-0.78), P < 0.0001; exon 20: HR = 1.46 (95% CI: 0.96-2.21), P = 0.07]. First-line treatment choice did not influence OS in multivariate analysis. First-line TKI predicted improved progression-free survival versus chemotherapy [HR = 0.67 (95% CI: 0.53-0.85), P = 0.001]. OS was longer for del19 versus L858R, which was associated with better OS compared with other exon 21 mutations, including L861Q. TKI improved survival in patients with exon 18 mutations, while chemotherapy was more beneficial for exon 20-mutated patients. CONCLUSION EGFR mutation type can inform the most appropriate treatment. Therapeutic schedule had no impact on OS in our study, although TKI should be prescribed in first-line considering the risk of missing the opportunity to use this treatment.
Collapse
Affiliation(s)
- C Leduc
- Department of Chest, Centre Hospitalier Universitaire de Strasbourg, Nouvel Hôpital Civil, Strasbourg
| | - J P Merlio
- Department of Biology and Pathology, Centre Hospitalier Universitaire de Bordeaux, Pessac;; Histology and Molecular Pathology of Tumors, Université de Bordeaux, Bordeaux
| | - B Besse
- Medicine Department, Gustave Roussy Cancer Campus, Villejuif
| | - H Blons
- INSERM UMR-S1147, Université Sorbonne Paris Cité, Paris;; Department of Biochemistry, Pharmacogenetics and Molecular Oncology, Hôpital Européen Georges Pompidou (HEGP), Assistance Publique - Hôpitaux de Paris, Paris
| | - D Debieuvre
- Department of Chest, Hôpital Emile Muller - GHRMSA, Mulhouse
| | - P P Bringuier
- Department of Biology and Pathology, Hospices Civils de Lyon, Lyon;; Université Claude Bernard Lyon 1, Lyon
| | - I Monnet
- Pneumology Department, Centre Hospitalier Intercommunal de Créteil, Créteil
| | - I Rouquette
- Pathology Department, Centre Hospitalier Universitaire de Toulouse Institut Universitaire du Cancer de Toulouse, Oncopôle, Toulouse
| | | | - A Lemoine
- Biochemistry and Oncogenetic Department, Oncomolpath, Assistance Publique - Hôpitaux de Paris, Paris;; Groupe Hospitalier des Hôpitaux Universitaires Paris-Sud, Université Paris 11, Villejuif
| | - D Pouessel
- Medical Oncology Department, Hôpital Saint Louis, Assistance Publique - Hôpitaux de Paris, Paris
| | - J Mosser
- Department of Molecular Genetics and Genomics - Medical Genomics, Centre Hospitalier Universitaire de Rennes, Rennes
| | - F Vaylet
- Department of Chest, Hôpital d'Instruction des Armées Percy, Clamart
| | - A Langlais
- Department of Biostatistics, Francophone de Cancérologie Thoracique, Paris
| | - P Missy
- Clinical Research Unit, Intergroupe Francophone de Cancérologie Thoracique, Paris
| | - F Morin
- Clinical Research Unit, Intergroupe Francophone de Cancérologie Thoracique, Paris
| | - D Moro-Sibilot
- Thoracic Oncology Unit, Centre Hospitalier Universitaire Grenoble-Alpes, Clinique de Pneumologie, Grenoble
| | - J Cadranel
- Department of Chest, Assistance Publique - Hôpitaux de Paris, Hôpital Tenon, Paris;; Sorbonne Université, UPMC Univ Paris 06, GRC n-04, Theranoscan, Paris
| | - F Barlesi
- Assistance Publique - Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Centre d'Investigation Clinique, Marseille
| | - M Beau-Faller
- Laboratory of Biochemistry and Molecular Biology, Centre Hospitalier Universitaire de Strasbourg, Hôpital de Hautepierre, Strasbourg;; EA3430 "Progression Tumorale et Microenvironnement, Approches Translationnelles et Épidémiologie," Strasbourg, France.
| |
Collapse
|
33
|
Amat F, Kouche C, Gaspard W, Lemoine A, Guiddir T, Lambert N, Zakariya M, Ridray C, Nemni A, Saint-Pierre P, Deschildre A, Couderc R, Just J. Is a slow-progression baked milk protocol of oral immunotherapy always a safe option for children with cow's milk allergy? A randomized controlled trial. Clin Exp Allergy 2017; 47:1491-1496. [DOI: 10.1111/cea.13022] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- F. Amat
- Department of Allergology; Centre de l'Asthme et des Allergies; Hôpital d'Enfants; Armand Trousseau; Assistance Publique-Hôpitaux de Paris; Paris France
- UPMC Univ Paris 06; Sorbonne Universités; Paris France
- Equipe EPAR; Institut Pierre Louis d'Epidémiologie et de Santé Publique; UMR_S1136, INSERM; Paris France
| | - C. Kouche
- Department of Allergology; Centre de l'Asthme et des Allergies; Hôpital d'Enfants; Armand Trousseau; Assistance Publique-Hôpitaux de Paris; Paris France
| | - W. Gaspard
- Department of Allergology; Centre de l'Asthme et des Allergies; Hôpital d'Enfants; Armand Trousseau; Assistance Publique-Hôpitaux de Paris; Paris France
| | - A. Lemoine
- Department of Allergology; Centre de l'Asthme et des Allergies; Hôpital d'Enfants; Armand Trousseau; Assistance Publique-Hôpitaux de Paris; Paris France
| | - T. Guiddir
- Department of Allergology; Centre de l'Asthme et des Allergies; Hôpital d'Enfants; Armand Trousseau; Assistance Publique-Hôpitaux de Paris; Paris France
- UPMC Univ Paris 06; Sorbonne Universités; Paris France
| | - N. Lambert
- Department of Allergology; Centre de l'Asthme et des Allergies; Hôpital d'Enfants; Armand Trousseau; Assistance Publique-Hôpitaux de Paris; Paris France
| | - M. Zakariya
- Department of Allergology; Centre de l'Asthme et des Allergies; Hôpital d'Enfants; Armand Trousseau; Assistance Publique-Hôpitaux de Paris; Paris France
| | - C. Ridray
- Department of Allergology; Centre de l'Asthme et des Allergies; Hôpital d'Enfants; Armand Trousseau; Assistance Publique-Hôpitaux de Paris; Paris France
| | - A. Nemni
- Department of Allergology; Centre de l'Asthme et des Allergies; Hôpital d'Enfants; Armand Trousseau; Assistance Publique-Hôpitaux de Paris; Paris France
| | - P. Saint-Pierre
- Equipe EPAR; Institut Pierre Louis d'Epidémiologie et de Santé Publique; UMR_S1136, INSERM; Paris France
- Institut de Mathématiques de Toulouse; Université Toulouse III Paul Sabatier; Toulouse France
| | - A. Deschildre
- Laboratory of Molecular Biology; Hôpital d'Enfants Armand Trousseau; Assistance Publique-Hôpitaux de Paris; Paris France
| | - R. Couderc
- CHRU Lille; Pediatric Pulmonology and Allergy Department; Hôpital Jeanne de Flandre; Lille France
| | - J. Just
- Department of Allergology; Centre de l'Asthme et des Allergies; Hôpital d'Enfants; Armand Trousseau; Assistance Publique-Hôpitaux de Paris; Paris France
- UPMC Univ Paris 06; Sorbonne Universités; Paris France
- Equipe EPAR; Institut Pierre Louis d'Epidémiologie et de Santé Publique; UMR_S1136, INSERM; Paris France
| |
Collapse
|
34
|
Leduc C, Pencreach E, Merlio JP, Bringuier PP, de Fraipont F, Escande F, Lemoine A, L'Houcine O, Blons H, Denis M, Hofman P, Lacave R, Melaabi S, Langlais A, missy P, Morin F, Barlesi F, Moro-Sibilot D, Cadranel J, Beau-Faller M. Ultrasensitive detection of EGFR T790M mutation by droplet digital PCR (ddPCR) in TKI naïve non-small cell lung cancer (NSCLC) harboring EGFR mutation: Results of the nationwide program Biomarkers France of the French Cooperative Thoracic Intergroup (IFCT). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Affiliation(s)
- A. Lemoine
- Faculté des Sciences du sport, Campus Universitaire Le Bailly, Allée P. Grousset, 80025 Amiens Cedex
| | - H. Jullien
- Faculté des Sciences du sport, Campus Universitaire Le Bailly, Allée P. Grousset, 80025 Amiens Cedex
| | - S. Ahmaidi
- Faculté des Sciences du sport, Campus Universitaire Le Bailly, Allée P. Grousset, 80025 Amiens Cedex
| |
Collapse
|
36
|
Fallet V, Saffroy R, Girard N, Mazières J, Moro-Sibilot D, Lantuejoul S, Rouquette I, Thivolet-Bejui F, Vieira T, Antoine M, Cadranel J, Lemoine A, Wislez M. Recherche de mutation de l’exon 14 de MET au sein des carcinomes sarcomatoïdes pulmonaires : étude multicentrique rétrospective. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
37
|
Guibert N, Barlesi F, Descourt R, Léna H, Besse B, Beau-Faller M, Mosser J, Pichon E, Merlio JP, Ouafik L, Guichard F, Mastroianni B, Moreau L, Wdowik A, Sabourin JC, Lemoine A, Missy P, Langlais A, Moro-Sibilot D, Mazières J. Caractéristiques et réponses aux traitements des patients porteurs de cancers du poumon non à petites cellules (CBNPC) avec altérations moléculaires multiples : analyse de l’étude Biomarqueurs France (IFCT). Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
38
|
Leduc C, Blons H, Besse B, Merlio J, Debieuvre D, Lemoine A, Monnet I, Pouessel D, Bringuier P, Poudenx M, Rouquette I, Vaylet F, Morin F, Langlais A, Quoix E, Zalcman G, Moro-Sibilot D, Cadranel J, Beau-Faller M, Barlesi F. Caractéristiques cliniques et moléculaires des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) avec mutation de l’EGFR : étude ancillaire de l’étude IFCT biomarqueurs France. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
39
|
Saffroy R, Suybeng V, Bosselut N, Hamelin J, Becker M, Pham P, Khoja C, Morère JF, Lemoine A. Ultra-sensitive mass spectrometry allows 33% increased detection of somatic EGFR T790M mutation in plasma cfDNA samples. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Leduc C, Blons H, Besse B, Merlio JP, Debieuvre D, Lemoine A, Monnet I, Pouessel D, Bringuier P, Poudenx M, Rouquette I, Vaylet F, Morin F, Langlais A, Quoix E, Zalcman G, Moro-Sibilot D, Cadranel J, Beau-Faller M, Barlesi F. Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Pincez T, Calamy L, Germont Z, Lemoine A, Lopes AA, Massiot A, Tencer J, Thivent C, Hadchouel A. [Pulmonary complications of sickle cell disease in children]. Arch Pediatr 2016; 23:1094-1106. [PMID: 27642150 DOI: 10.1016/j.arcped.2016.06.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Revised: 03/21/2016] [Accepted: 06/29/2016] [Indexed: 01/01/2023]
Abstract
Acute and chronic pulmonary complications are frequent in sickle cell disease (SCD), with different spectrum and characteristics in children and adults. Chronic hypoxia is frequent and plays a role in several respiratory complications in SCD. Furthermore, hypoxia has been associated with a higher risk of cerebral ischemia. Despite differing oxygen affinity between hemoglobin A and S, standard pulse oximetry was shown to be accurate in diagnosing hypoxia in SCD patients. Whereas acute hypoxia management is similar to non-SCD patients, chronic hypoxia treatment is mainly based on a transfusion program rather than long-term oxygen therapy. Acute chest syndrome (ACS) is the foremost reason for admission to the intensive care unit and the leading cause of premature death. Guidelines on its management have recently been published. Asthma appears to be a different comorbidity and may increase the risk of vaso-occlusive crisis, ACS, and early death. Its management is not specific in SCD, but systemic steroids must be used carefully. Pulmonary hypertension (PH) is a major risk factor of death in adult patients. In children, no association between PH and death has been shown. Elevated tricuspid regurgitant velocity was associated with lower performance on the 6-min walk test (6MWT) but its long-term consequences are still unknown. These differences could be due to different pathophysiology mechanisms. Systematic screening is recommended in children. Regarding lung functions, although obstructive syndrome appears to be rare, restrictive pattern prevalence increases with age in SCD patients. Adaptation to physical exercise is altered in SCD children: they have a lower walking distance at the 6MWT than controls and can experience desaturation during effort, but muscular blood flow regulation maintains normal muscular strength. Sleeping disorders are frequent in SCD children, notably Obstructive sleep apnea syndrome (OSAS). Because of the neurological burden of nocturnal hypoxia, OSAS care is primordial and mainly based on adenotonsillectomy, which has been shown to reduce ischemic events. The high morbidity and mortality related to pulmonary impairments in SCD require a careful pulmonary assessment and follow-up. Mainly based on clinical examination, follow-up aims to the diagnosis of SCD-related respiratory complications early in these children.
Collapse
Affiliation(s)
- T Pincez
- Service d'hémato-oncologie pédiatrique, AP-HP, hôpital universitaire Armand-Trousseau, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France
| | - L Calamy
- Service de neurologie pédiatrique, AP-HP, hôpital du Kremlin Bicêtre, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - Z Germont
- Service d'hémato-oncologie pédiatrique, AP-HP, hôpital universitaire Armand-Trousseau, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France
| | - A Lemoine
- Service de gastro-entérologie et nutrition pédiatriques, AP-HP, hôpital universitaire Armand-Trousseau, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France
| | - A-A Lopes
- Service de réanimation néonatale et soins intensifs, centre hospitalier de Meaux, 6-8, rue Saint-Fiacre, BP 218, 77104 Meaux cedex, France
| | - A Massiot
- Service de pneumologie pédiatrique, AP-HP, hôpital universitaire Armand-Trousseau, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France
| | - J Tencer
- Service de neurologie pédiatrique, AP-HP, hôpital universitaire Robert-Debré, 48, boulevard Sérurier, 75019 Paris, France
| | - C Thivent
- Service de neurologie pédiatrique, AP-HP, hôpital universitaire Armand-Trousseau, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France
| | - A Hadchouel
- Service de pneumologie et d'allergologie pédiatriques, AP-HP, hôpital universitaire Necker-Enfants-Malades, 149, rue de Sèvres, 75046 Paris cedex 15, France; Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France; Équipe 4, Inserm, U955, 94000 Créteil, France.
| |
Collapse
|
42
|
Lemoine A, Salem J, Harbison M, Tounian P, Netchine I, Dubern B. Effet de la cyproheptadine sur la croissance staturopondérale des enfants atteints du syndrome de Silver-Russell. NUTR CLIN METAB 2016. [DOI: 10.1016/j.nupar.2016.09.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
43
|
Assouline P, Léger-Ravet MB, Saffroy R, Hamelin J, Bénissad A, Husleag P, Lemoine A, Oliviéro G. [Breast metastases from lung cancers with the EGFR mutation]. Rev Mal Respir 2016; 34:61-65. [PMID: 27282326 DOI: 10.1016/j.rmr.2016.04.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2016] [Accepted: 04/27/2016] [Indexed: 12/16/2022]
Abstract
INTRODUCTION The breast is a rare site for metastases from lung cancers. Their occurrence in patients with adenocarcinoma which has the EGFR mutation is exceptional. In this context, it is sometimes difficult to differentiate a second primary breast cancer from a breast metastasis. OBSERVATIONS We report the cases of two patients who developed breast metastases from lung adenocarcinoma that was TTF1 positive with a deletion of exon 19 of the EGFR gene. A non-smoking woman of Asian origin, presented with a solitary breast metastasis 29 months after being established on first-line chemotherapy. The second case was a Caucasian patient who was an active smoker presented with tumor progression with multiple metastases including involvement of both breasts 10 months after the start of treatment with a tyrosine kinase inhibitor. In both, tumor cells from the breast showed positive immunostaining for TTF1 and genotyping detected the presence of the deletion of exon 19 of the EGFR gene. CONCLUSION In patients with lung adenocarcinoma and EGFR mutation, immunohistochemical examination, including TTF1 and genotyping of synchronous breast tumour, is needed to confirm its metastatic nature and to guide treatment.
Collapse
Affiliation(s)
- P Assouline
- Service de pneumologie et d'oncologie thoracique, groupe hospitalier Nord Essonne, 159, rue du Président-François-Mitterrand, 91160 Longjumeau cedex 01, France.
| | - M-B Léger-Ravet
- Service d'anatomie et de cytologie pathologiques, groupe hospitalier Nord Essonne, 91160 Longjumeau cedex 01, France
| | - R Saffroy
- Service de biochimie et d'oncogénétique, hôpital Paul-Brousse, Assistance publique-Hôpitaux de Paris, 12, avenue Paul-Vaillant-Couturier, 94800 Villejuif, France
| | - J Hamelin
- Service de biochimie et d'oncogénétique, hôpital Paul-Brousse, Assistance publique-Hôpitaux de Paris, 12, avenue Paul-Vaillant-Couturier, 94800 Villejuif, France
| | - A Bénissad
- Service d'imagerie médicale, groupe hospitalier Nord Essonne, 91160 Longjumeau cedex 01, France
| | - P Husleag
- Service de pneumologie et d'oncologie thoracique, groupe hospitalier Nord Essonne, 159, rue du Président-François-Mitterrand, 91160 Longjumeau cedex 01, France
| | - A Lemoine
- Service de biochimie et d'oncogénétique, hôpital Paul-Brousse, Assistance publique-Hôpitaux de Paris, 12, avenue Paul-Vaillant-Couturier, 94800 Villejuif, France
| | - G Oliviéro
- Service de pneumologie et d'oncologie thoracique, groupe hospitalier Nord Essonne, 159, rue du Président-François-Mitterrand, 91160 Longjumeau cedex 01, France
| |
Collapse
|
44
|
Fallet V, Saffroy R, Girard N, Mazieres J, Lantuejoul S, Vieira T, Rouquette I, Thivolet-Bejui F, Ung M, Poulot V, Schlick L, Moro-Sibilot D, Antoine M, Cadranel J, Lemoine A, Wislez M. High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets. Ann Oncol 2015; 26:1748-53. [DOI: 10.1093/annonc/mdv232] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2015] [Accepted: 05/07/2015] [Indexed: 02/06/2023] Open
|
45
|
Mahamodo S, Rivière C, Neut C, Abedini A, Ranarivelo H, Duhal N, Roumy V, Hennebelle T, Sahpaz S, Lemoine A, Razafimahefa D, Razanamahefa B, Bailleul F, Andriamihaja B. Antimicrobial prenylated benzoylphloroglucinol derivatives and xanthones from the leaves of Garcinia goudotiana. Phytochemistry 2014; 102:162-168. [PMID: 24690454 DOI: 10.1016/j.phytochem.2014.03.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2014] [Revised: 03/03/2014] [Accepted: 03/06/2014] [Indexed: 06/03/2023]
Abstract
Bioassay-guided fractionation using antimicrobial assay of the crude acetonic extract of Garcinia goudotiana leaves and of its five partitions led to the isolation of two new prenylated benzoylphloroglucinol derivatives, goudotianone 1 (1) and goudotianone 2 (2), in addition to two known compounds including one xanthone, 1,3,7-trihydroxy-2-isoprenylxanthone (3), and one triterpenoid, friedelin (4). Their structures were elucidated on the basis of different spectroscopic methods, including extensive 1D- and 2D-NMR spectroscopy and mass spectrometry. The crude acetonic extract, the methylene chloride and ethyl acetate partitions, and some tested compounds isolated from this species (1-3) demonstrated selective significant antimicrobial activities against Gram-positive bacteria, in particular Staphylococcus lugdunensis, Enterococcus faecalis and Mycobacterium smegmatis. The potential cytotoxic activities of these extracts and compounds were evaluated against human colon carcinoma HT29 and human fetal lung fibroblast MRC5 cells.
Collapse
Affiliation(s)
- Sania Mahamodo
- Laboratoire de Chimie Appliquée aux Substances Naturelles, Faculté des Sciences, Université d'Antananarivo, BP 566, Antananarivo 101, Madagascar; Institut Régional de Recherche en Agroalimentaire et Biotechnologie: Charles Viollette, EA1026, Université Lille 2, F-59000 Lille, France; EA GRIIOT, EA4481, Laboratoire de pharmacognosie, UFR Pharmacie, Université Lille 2, F-59000 Lille, France
| | - Céline Rivière
- Institut Régional de Recherche en Agroalimentaire et Biotechnologie: Charles Viollette, EA1026, Université Lille 2, F-59000 Lille, France; EA GRIIOT, EA4481, Laboratoire de pharmacognosie, UFR Pharmacie, Université Lille 2, F-59000 Lille, France.
| | - Christel Neut
- INSERM U995, UFR Pharmacie, Université Lille 2, F-59000 Lille, France
| | - Amin Abedini
- Institut Régional de Recherche en Agroalimentaire et Biotechnologie: Charles Viollette, EA1026, Université Lille 2, F-59000 Lille, France; EA GRIIOT, EA4481, Laboratoire de pharmacognosie, UFR Pharmacie, Université Lille 2, F-59000 Lille, France
| | | | - Nathalie Duhal
- CUMA, UFR Pharmacie, Université Lille 2, F-59000 Lille, France
| | - Vincent Roumy
- Institut Régional de Recherche en Agroalimentaire et Biotechnologie: Charles Viollette, EA1026, Université Lille 2, F-59000 Lille, France; EA GRIIOT, EA4481, Laboratoire de pharmacognosie, UFR Pharmacie, Université Lille 2, F-59000 Lille, France
| | - Thierry Hennebelle
- Institut Régional de Recherche en Agroalimentaire et Biotechnologie: Charles Viollette, EA1026, Université Lille 2, F-59000 Lille, France; EA GRIIOT, EA4481, Laboratoire de pharmacognosie, UFR Pharmacie, Université Lille 2, F-59000 Lille, France
| | - Sevser Sahpaz
- Institut Régional de Recherche en Agroalimentaire et Biotechnologie: Charles Viollette, EA1026, Université Lille 2, F-59000 Lille, France; EA GRIIOT, EA4481, Laboratoire de pharmacognosie, UFR Pharmacie, Université Lille 2, F-59000 Lille, France
| | - Amélie Lemoine
- EA GRIIOT, EA4481, Laboratoire de pharmacognosie, UFR Pharmacie, Université Lille 2, F-59000 Lille, France
| | - Dorothée Razafimahefa
- Laboratoire de Chimie Appliquée aux Substances Naturelles, Faculté des Sciences, Université d'Antananarivo, BP 566, Antananarivo 101, Madagascar
| | - Bakonirina Razanamahefa
- Laboratoire de Chimie Appliquée aux Substances Naturelles, Faculté des Sciences, Université d'Antananarivo, BP 566, Antananarivo 101, Madagascar
| | - François Bailleul
- Institut Régional de Recherche en Agroalimentaire et Biotechnologie: Charles Viollette, EA1026, Université Lille 2, F-59000 Lille, France; EA GRIIOT, EA4481, Laboratoire de pharmacognosie, UFR Pharmacie, Université Lille 2, F-59000 Lille, France
| | - Bakolinirina Andriamihaja
- Laboratoire de Chimie Appliquée aux Substances Naturelles, Faculté des Sciences, Université d'Antananarivo, BP 566, Antananarivo 101, Madagascar
| |
Collapse
|
46
|
Tufo G, Jones AWE, Wang Z, Hamelin J, Tajeddine N, Esposti DD, Martel C, Boursier C, Gallerne C, Migdal C, Lemaire C, Szabadkai G, Lemoine A, Kroemer G, Brenner C. The protein disulfide isomerases PDIA4 and PDIA6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma. Cell Death Differ 2014; 21:685-95. [PMID: 24464223 PMCID: PMC3978299 DOI: 10.1038/cdd.2013.193] [Citation(s) in RCA: 96] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2013] [Revised: 11/14/2013] [Accepted: 12/02/2013] [Indexed: 01/03/2023] Open
Abstract
Intrinsic and acquired chemoresistance are frequent causes of cancer eradication failure. Thus, long-term cis-diaminedichloroplatine(II) (CDDP) or cisplatin treatment is known to promote tumor cell resistance to apoptosis induction via multiple mechanisms involving gene expression modulation of oncogenes, tumor suppressors and blockade of pro-apoptotic mitochondrial membrane permeabilization. Here, we demonstrate that CDDP-resistant non-small lung cancer cells undergo profound remodeling of their endoplasmic reticulum (ER) proteome (>80 proteins identified by proteomics) and exhibit a dramatic overexpression of two protein disulfide isomerases, PDIA4 and PDIA6, without any alteration in ER-cytosol Ca(2+) fluxes. Using pharmacological and genetic inhibition, we show that inactivation of both proteins directly stimulates CDDP-induced cell death by different cellular signaling pathways. PDIA4 inactivation restores a classical mitochondrial apoptosis pathway, while knockdown of PDIA6 favors a non-canonical cell death pathway sharing some necroptosis features. Overexpression of both proteins has also been found in lung adenocarcinoma patients, suggesting a clinical importance of these proteins in chemoresistance.
Collapse
Affiliation(s)
- G Tufo
- INSERM UMR-S 769, LabEx LERMIT, Châtenay-Malabry, France
- Faculté de Pharmacie, Université de Paris-Sud, Châtenay-Malabry, France
| | - A W E Jones
- Department of Cell and Developmental Biology, University College London, London, UK
| | - Z Wang
- INSERM UMR-S 769, LabEx LERMIT, Châtenay-Malabry, France
- Faculté de Pharmacie, Université de Paris-Sud, Châtenay-Malabry, France
| | - J Hamelin
- APHP Hôpital P. Brousse, Biochimie et oncogénétique, INSERM U1004, Villejuif, France
| | - N Tajeddine
- INSERM U848, Institut Gustave Roussy, Université Paris-Sud 11, PR1, 39 rue Camille Desmoulins, Villejuif, France
| | - D D Esposti
- APHP Hôpital P. Brousse, Biochimie et oncogénétique, INSERM U1004, Villejuif, France
| | - C Martel
- INSERM UMR-S 769, LabEx LERMIT, Châtenay-Malabry, France
- Faculté de Pharmacie, Université de Paris-Sud, Châtenay-Malabry, France
- Montreal Heart Institute, Centre de Recherche, Montreal, Quebec, Canada
| | | | - C Gallerne
- INSERM UMR-S 769, LabEx LERMIT, Châtenay-Malabry, France
- Faculté de Pharmacie, Université de Paris-Sud, Châtenay-Malabry, France
| | - C Migdal
- Faculté de Pharmacie, Université de Paris-Sud, Châtenay-Malabry, France
- INSERM U 996, Châtenay-Malabry, France
| | - C Lemaire
- INSERM UMR-S 769, LabEx LERMIT, Châtenay-Malabry, France
- Department of Biology, University of Versailles–St Quentin, Versailles, France
| | - G Szabadkai
- Department of Cell and Developmental Biology, University College London, London, UK
- Department of Biomedical Sciences, University of Padua, Padua, Italy
| | - A Lemoine
- APHP Hôpital P. Brousse, Biochimie et oncogénétique, INSERM U1004, Villejuif, France
| | - G Kroemer
- INSERM U848, Institut Gustave Roussy, Université Paris-Sud 11, PR1, 39 rue Camille Desmoulins, Villejuif, France
- Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France
- Metabolomics Platform, Institut Gustave Roussy, Villejuif, France
- Equipe 11 labellisée par la Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France
- Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France
| | - C Brenner
- INSERM UMR-S 769, LabEx LERMIT, Châtenay-Malabry, France
- Faculté de Pharmacie, Université de Paris-Sud, Châtenay-Malabry, France
| |
Collapse
|
47
|
Jurkolow G, Fuchs-Buder T, Lemoine A, Raft J, Rocq N, Meistelman C. [Prolonged phase II neuromuscular blockade following succinylcholine administration]. Ann Fr Anesth Reanim 2014; 33:176-177. [PMID: 24440731 DOI: 10.1016/j.annfar.2013.12.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/09/2013] [Accepted: 12/18/2013] [Indexed: 06/03/2023]
Abstract
Patients who are given a single dose of succinylcholine normally undergo a short-acting depolarizing phase I neuromuscular block but rarely a phase II block. Prolonged neuromuscular blockade occurs after a single dose of succinylcholine in case of genetically determined abnormal plasma butyrylcholinesterase activity. It is mandatory to use monitoring to detect this side effect. We report a case of a patient with abnormal plasma butyrylcholinesterase activity undergoing a six-hour prolonged neuromuscular phase II block, after a single dose of succinylcholine.
Collapse
Affiliation(s)
- G Jurkolow
- Département d'anesthésie-réanimation, université de Lorraine, CHU de Nancy-Brabois, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France.
| | - T Fuchs-Buder
- Département d'anesthésie-réanimation, université de Lorraine, CHU de Nancy-Brabois, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France
| | - A Lemoine
- Département d'anesthésie-réanimation, université de Lorraine, CHU de Nancy-Brabois, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France
| | - J Raft
- Département d'anesthésie-réanimation, ICL - institut de cancérologie de Lorraine, avenue de Bourgogne, 54511 Vandœuvre-lès-Nancy, France
| | - N Rocq
- Département d'anesthésie-réanimation, université de Lorraine, CHU de Nancy-Brabois, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France
| | - C Meistelman
- Département d'anesthésie-réanimation, université de Lorraine, CHU de Nancy-Brabois, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France; Département d'anesthésie-réanimation, ICL - institut de cancérologie de Lorraine, avenue de Bourgogne, 54511 Vandœuvre-lès-Nancy, France
| |
Collapse
|
48
|
Tourteau A, Andrzejak V, Body-Malapel M, Lemaire L, Lemoine A, Mansouri R, Djouina M, Renault N, El Bakali J, Desreumaux P, Muccioli GG, Lambert DM, Chavatte P, Rigo B, Leleu-Chavain N, Millet R. 3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis. Bioorg Med Chem 2013; 21:5383-94. [PMID: 23849204 DOI: 10.1016/j.bmc.2013.06.010] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2013] [Revised: 05/28/2013] [Accepted: 06/06/2013] [Indexed: 01/12/2023]
Abstract
Recent investigations showed that anandamide, the main endogenous ligand of CB1 and CB2 cannabinoid receptors, possesses analgesic, antidepressant and anti-inflammatory effects. In the perspective to treat inflammatory bowel disease (IBD), our approach was to develop new selective CB2 receptor agonists without psychotropic side effects associated to CB1 receptors. In this purpose, a new series of 3-carboxamido-5-aryl-isoxazoles, never described previously as CB2 receptor agonists, was designed, synthesized and evaluated for their biological activity. The pharmacological results have identified great selective CB2 agonists with in vivo anti-inflammatory activity in a DSS-induced acute colitis mouse model.
Collapse
Affiliation(s)
- Aurélien Tourteau
- Université Lille Nord de France, EA4481, Institut de Chimie Pharmaceutique Albert Lespagnol, IFR114, 3 Rue du Pr. Laguesse, BP83, F-59006 Lille, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Jiménez-Castro MB, Elias-Miro M, Mendes-Braz M, Lemoine A, Rimola A, Rodés J, Casillas-Ramírez A, Peralta C. Tauroursodeoxycholic acid affects PPARγ and TLR4 in Steatotic liver transplantation. Am J Transplant 2012; 12:3257-71. [PMID: 22994543 DOI: 10.1111/j.1600-6143.2012.04261.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Numerous steatotic livers are discarded for transplantation because of their poor tolerance to ischemia-reperfusion (I/R). We examined whether tauroursodeoxycholic acid (TUDCA), a known inhibitor of endoplasmic reticulum (ER) stress, protects steatotic and nonsteatotic liver grafts preserved during 6 h in University of Wisconsin (UW) solution and transplanted. The protective mechanisms of TUDCA were also examined. Neither unfolded protein response (UPR) induction nor ER stress was evidenced in steatotic and nonsteatotic liver grafts after 6 h in UW preservation solution. TUDCA only protected steatotic livers grafts and did so through a mechanism independent of ER stress. It reduced proliferator-activated receptor-γ (PPARγ) and damage. When PPARγ was activated, TUDCA did not reduce damage. TUDCA, which inhibited PPARγ, and the PPARγ antagonist treatment up-regulated toll-like receptor 4 (TLR4), specifically the TIR domain-containing adaptor inducing IFNβ (TRIF) pathway. TLR4 agonist treatment reduced damage in steatotic liver grafts. When TLR4 action was inhibited, PPARγ antagonists did not protect steatotic liver grafts. In conclusion, TUDCA reduced PPARγ and this in turn up-regulated the TLR4 pathway, thus protecting steatotic liver grafts. TLR4 activating-based strategies could reduce the inherent risk of steatotic liver failure after transplantation.
Collapse
Affiliation(s)
- M B Jiménez-Castro
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBPAS), Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Garofalo A, Farce A, Ravez S, Lemoine A, Six P, Chavatte P, Goossens L, Depreux P. Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors. J Med Chem 2012; 55:1189-204. [PMID: 22229669 DOI: 10.1021/jm2013453] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
In our continuing search for medicinal agents to treat proliferative diseases, quinazoline derivatives were synthesized and evaluated pharmacologically as epithelial growth factor receptor and vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase inhibitors. A quantitative structure-activity relationship analysis was conducted to rationalize the structure-activity relationship and to predict how similar the inhibitor-binding profiles of two protein kinases are likely to be on the basis of the docking of lead coumpounds into the ATP-binding site. This model was used to direct the synthesis of new compounds. A series of N-(aromatic)-N'-{4-[(6,7-dimethoxyquinazolin-4-yl)oxy]phenyl}urea were identified as potent and selective inhibitors of the tyrosine kinase activity of VEGFR-2 (fetal liver kinase 1, kinase insert domain-containing receptor). An efficient route was developed that enabled the synthesis of a wide variety of analogues with substitution on several positions of the template. Substitution of diarylurea, competitive with ATP, afforded several analogues with low nanomolar inhibition of enzymatic activity of VEGFR-2. In this paper, we describe the synthesis, structure-activity relationships, and pharmacological characterization of the series.
Collapse
|